Abstract

BackgroundEvaluation of disease activity is essential in decision of the treatment and monitoring the therapies in rheumatoid arthritis (RA). Rheumatoid Arthritis Disease Activity Index (RADAI) appears as an attractive form...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Performance of the Rheumatoid Arthritis Disease Activity Index in the Assessment of Disease Activity in Rheumatoid Arthritis-Findings From the REAL Study.
Leticia Rocha Pereira ... Maria Fernanda Brandão De Resende Guimarães
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases | VOL. 28
Leticia Rocha Pereira, et. al.Leticia Rocha Pereira ... Maria Fernanda Brandão De Resende Guimarães
22 Mar 2022
AB0238 USEFULNESS OF RAPID3 IN ASSESSING UNMET NEEDS OF RHEUMATOID ARTHRITIS PATIENTS FROM THE T-FLAG STUDY
K Terabe ... R Sato
Annals of the Rheumatic Diseases | VOL. 82
K Terabe, et. al.K Terabe ... R Sato
30 May 2023
Evaluation of disease activity in rheumatoid arthritis by Routine Assessment of Patient Index Data 3 (RAPID3) and its correlation to Disease Activity Score 28 (DAS28) and Clinical Disease Activity Index (CDAI): an Indian experience
H Kumar ... P Talapatra
Clinical Rheumatology | VOL. 31
H Kumar, et. al.H Kumar ... P Talapatra
15 Sep 2012
Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors.
Andrea Cuervo ... Sonia Raquel Cabrera‐Villalba
Arthritis care & research | VOL. 68
Andrea Cuervo, et. al.Andrea Cuervo ... Sonia Raquel Cabrera‐Villalba
23 Jun 2016
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers